The Zacks Analyst Blog Highlights:ViroPharma Inc, Halozyme Therapeutics, Lockheed Martin Corporation, The Boeing Company and

   The Zacks Analyst Blog Highlights:ViroPharma Inc, Halozyme Therapeutics,
     Lockheed Martin Corporation, The Boeing Company and General Dynamics
                                 Corporation

PR Newswire

CHICAGO, Nov. 15, 2012

CHICAGO, Nov. 15, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include ViroPharma Inc (VPHM), Halozyme
Therapeutics (HALO), Lockheed Martin Corporation (LMT), The Boeing Company
(BA) and General Dynamics Corporation (GD).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

Here are highlights from Thursday's Analyst Blog:

ViroPharma Presents Cinryze Data

ViroPharma Inc. (VPHM) presented promising data on Cinryze at the American
College of Allergy, Asthma and Immunology's (ACAAI) annual congress. Data was
presented from a post marketing study that evaluated the safety, tolerability
and efficacy of Cinryze in escalating doses in patients with hereditary
angioedema (HAE), who did not show sufficient treatment benefit with 1000
units every 3 or 4 days.

The open-label multicenter study enrolled 20 patients over a span of 3 years.
It was observed that doses up to 2500 units every 3 or 4 days can be
prescribed to patients who show insufficient response to bi-weekly 1000 units.
Additionally, Cinryze was found to be well tolerated and side effects observed
were consistent with previous studies.

We note that Cinryze is approved both in the US and Europe. In the US, the
drug is approved for routine prophylaxis against angioedema attacks in
adolescent and adult patients with HAE. In Europe, it is approved for routine
prevention, pre-procedure prevention and acute treatment of angioedema attacks
in adolescent and adult patients with HAE.

The company is also evaluating the subcutaneous administration of Cinryze in
combination with its partner, Halozyme Therapeutics' (HALO) recombinant human
hyaluronidase enzyme (rHuPH20). In September 2012, the US Food and Drug
Administration (FDA) removed a clinical hold on the phase II study. The
company plans to initiate a phase II study in the EU shortly.

In the third quarter of 2012, Cinryze's net sales climbed 30.4% y/y to $85.3
million, driven by higher demand. Bulk of the sales ($84 million) came from
the US. US sales were reflective of patient demand ($82 million) and inventory
build up ($2 billion), according to management.

Recommendation

We currently have a Neutral recommendation on ViroPharma. The stock carries a
Zacks #3 Rank (Hold rating) in the short run.

We are encouraged by Cinryze's sales growth and patient additions in the third
quarter of 2012. However, we remain concerned about the lack of late-stage
pipeline candidates and the company's dependency on Cinryze for growth.

Lockheed Acquires Chandler/Ray

Lockheed Martin Corporation (LMT) announced the acquisition of Chandler/May
Inc., an unmanned aerial systems manufacturer. Terms of the agreement,
however, remained undisclosed. Chandler/May, with facilities in Alabama and
California, will become part of Lockheed's Mission Systems & Sensors business.
Lockheed Martin's prudent acquisition of Chandler/May would expand its
expertise in the design, development, integration, manufacturing, and support
of fully integrated mission critical systems for unmanned aerial systems
("UAS") and Command, Control, Communications, Computers, Intelligence,
Surveillance, Reconnaissance ("C4ISR") missions.

Based in Bethesda, Maryland, Lockheed Martin is a global security and
aerospace company, engaged in the research, design, development, manufacture,
integration and sustainment of advanced technology systems, products and
services. Key growth drivers of the company are its focus on debt repayment,
its ongoing share repurchase program and the incremental dividend. Some of
Lockheed Martin's main competitors are The Boeing Company (BA) and General
Dynamics Corporation (GD).

Lockheed Martin recently reported strong third quarter numbers with earnings
of $2.26 per share beating the Zacks Consensus Estimate of $1.85. With this
the company also beat the year-ago earnings of $2.06 per share.

Lockheed Martin reported quarterly revenue of $11.9 billion, beating the Zacks
Consensus Estimate of $11.1 billion. However, the figure fell below the
year-ago quarterly revenue of $12.1 billion.

During the third quarter, the company repurchased 3.3 million shares at a cost
of $294 million. In September this year, the company increased its quarterly
dividend rate to $1.15 per share, up approximately 15 cents from the current
payout of approximately $1.00 per share. The proposed hike would bring the
annual dividend to $4.60, up 15% from the previous payout. The increased
quarterly dividend will be paid on December 28, 2012 to shareholders of record
at the close of business on December 3, 2012.

Going forward, we believe Lockheed Martin has significant upside potential
based on the Obama administration's focus on Intelligence Surveillance
Reconnaissance ("ISR"), unmanned systems, force protection, cybersecurity, and
missile defense. It already sits on an order backlog of approximately $75.6
billion at the end of the first nine months of 2012.

Further, we expect shareholder return to continue to be shored up by the
company's focus on debt repayment, its ongoing share repurchase program and
the incremental dividend.

However, we are concerned about the budget deficits and political uncertainty
that make future defense budgets vulnerable to cutbacks. Lockheed Martin
presently retains a short-term Zacks #3 Rank (Hold) that corresponds with our
long-term Neutral recommendation on the stock.

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks
are offered free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.